Friday, 19 Jul 2019

PsA/SpA

Datesort ascending Type Title Save
13 May 2019 News Low Serious Infection Risk with Newer Agents in Psoriasis
08 May 2019 Social Long term safety of Secukinumab in PsO, PsA, & AS RCTs ( 96,054 patient-years) - favorable results with low incidence of serious infx (1.4, 1.9, 1.2, /100PYs), Candida (2.2, 1.5, 0.7/100pYs), IBD (0.01, 0.05, and 0.1/100PYs) or MACE (0.3, 0.4, 0.6). No TB. https://t.co/BTbBlOYj8W
02 May 2019 Social French real-world study of Psoriatic arthritis pts starting apremilast (n 3207) or MTX (n 2736), finds higher discontinuation rates at 1 yr for apremilast (69%) vs MTX (59%) https://t.co/bhPwaPhX23
29 Apr 2019 ACR Video RheumNow Live Preview with Dr. Elaine Husni (The Changing Paradigm in Spondylitis)
24 Apr 2019 News Skyrizi (risankizumab) FDA Approved for Psoriasis
19 Apr 2019 News Higher Comorbidities in Hidradenitis Suppurativa
17 Apr 2019 Social Comparing fibromyalgia, PsA, Psoriasis Pts - FM has more entheseal tenderness (92%) than PSA (66%) and PSO (59%). However with ultrasound, entheseal involvement were more frequent in PsA & psoriasis (~90%) vs FM (75%). What? US enthesitis in FM? https://t.co/wNBQEB3j0O
16 Apr 2019 ACR Video RheumNow Live Preview with Dr. Eric Ruderman
15 Apr 2019 ACR Video RheumNow Live Preview with Dr. Philip Conaghan
11 Apr 2019 ACR Video RheumNow Live Preview with Dr. Arthur Kavanaugh
10 Apr 2019 Social Claims data shows among 60 028 psoriasis or psoriatic arthritis pts, there was NO significant difference in the risk of developing atrial fibrillation or major adverse cardiovascular events with ustekinumab (vs a TNF inhibitor) https://t.co/kJhUsmupLx
08 Apr 2019 Social 41 study Metanalysis on H zoster drug risk in psoriasis and PsA - finds an increased risk w/ steroids, tofacitinib, biologic +DMARD Combination Rx. But no risk with monotherapy. Insufficient evidence for IL-12/23, -7, -23 inhibitors or apremilast https://t.co/KRrTqIw7Ko
04 Apr 2019 Social RT @MedReuma: Do female vs. male patients with AS #spondyloarthritis present differently? Dr Husni #RNL2019 https://t.co/ZEGuRzxGUn
04 Apr 2019 Social Dr Craig Leonardi's review of Effective biologics to achieve a PASI 100 in Psoriasis. The newer agents are far ahead! #RNL2019 https://t.co/p71hb58SAf
04 Apr 2019 Social RT @MedReuma: 2016 ASAS-EULAR treatment recommendations for axSpA Dr Ruderman #Spondylitis #RNL2019 https://t.co/NtIPbryT5y
04 Apr 2019 Social RT @KDAO2011: Updates to ASAS guidelines #rnl2019 Dr Ruderman https://t.co/pkoGhToY99
03 Apr 2019 Social RT @caocosm: Important point! - Many patients with SpA may have FMS - BUT - FMS patients don't meet SpA criteria. - Dr Eric Ruderman @Joint…
02 Apr 2019 ACR Video RNL Intro - Dr. Artie Kavanaugh Emerging Trends in PsA
02 Apr 2019 Social RT @KDAO2011: Distinguishing b/t AS and nonradiographic SpA (AS more likely to be males; higher CRP); nonradiographic SpA more likely femal…
01 Apr 2019 Social RT @RheumNow: Dr Phil Conaghan on the similarity between OA and PsA #RNL2019 https://t.co/za9YDAWilE